当前位置: 首页 > 期刊 > 《实用老年医学》 > 2000年第1期
编号:11399680
缬沙坦对慢性非瓣膜性心房颤动者左房重塑的干预研究
http://www.100md.com 《实用老年医学》 2000年第1期
缬沙坦;,心房颤动;,老年人,【主题词】缬沙坦;心房颤动;老年人,1对象与方法,2结果,3讨论,参考文献
     【摘要】 目的 观察缬沙坦对老年慢性非瓣膜性心房颤动(Af)患者左房重塑的影响并探讨其作用机制。 方法 选择54例老年慢性非瓣膜性心房颤动患者(病史>6月),随机分为缬沙坦组和对照组,2组常规治疗无明显差异,缬沙坦组加用缬沙坦 80 mg/d,疗程为12月。应用超声心动图记录50例窦性心律者(窦律组)及2组Af患者治疗前及治疗3、6、12月后左房内径(LAD),同时应用放射免疫分析法测定血清Ⅲ型前胶原末端肽(PⅢP)含量,随访治疗期间心脑血管事件的发生。 结果 Af患者LAD、PⅢP较窦律组明显增高。治疗前及治疗后3月、6月,2组Af患者LAD无明显差异(P>005);治疗12月后对照组LAD明显大于缬沙坦组(P<001);从治疗后6月起缬沙坦组PⅢP即有明显下降,与对照组相比差异显著(P<005,P<001);且PⅢP含量与左房内径呈正相关(r=04785,P<001);治疗期间缬沙坦组心脑血管事件发生率明显低于对照组(P<001) 结论 缬沙坦可能通过抑制心房局部肾素血管紧张素系统(RAS),减少心肌胶原的合成与分泌,减轻心房纤维化,阻抑左房进行性扩大,改善心房顺应性,降低Af患者心脑血管事件的发生。

    【主题词】 缬沙坦; 心房颤动; 老年人

    The effects of Valsartan on left atrial remodeling in elderly patients with chronic nonvalvular atrial fibrillation

    CHEN Yueyun, WANG Jun, XIA Chaohong, YANG Yuwen, WANG Yuanjing, ZHANG Pingyang.

    Yijishan Hospital, Wannan Medical College, Wuhu 241000 China

    【Abstract】 Objective To explore the effects of Valsartan on left atrial remodeling in elderly patients with chronic nonvalvular atrial fibrillation(Af). Methods The 54 patients with Af were randomly divided into two groups: Valsartan group and control group, with no difference about routine treatments in both groups. Valsartan 80mg/d was added in valsartan group. The left atrial diameter(LAD) was measured in the stable sinus rhythm(SR) group(n=50) and the two groups of Af patients before and at the 3rd, 6rd,12rd month after treatment by doppler ultrasound, meanwhile, the level of serum procollagen Ⅲ (PⅢP) was measured by radioimmunoassay(RIA). The recurrence rate of cardiocerebral events were recorded in the term of treatments. Resukts The LAD, PⅢP in Af patients increased significantly than those in SR group. The difference of LAD was not significant between two groups of Af patients before and at the 3th month, 6th month after treatment .At the 12th month , there was significant difference between the two groups. The PⅢP decreased signifcicantly in Valsartan group from the 6th month after treatment than that in the control group(P<005,P<001). The PⅢP was related to the LAD(r=04785,P<001). The risk of cardiocerebral events in valsartan group was significantly lower than that in the control group. Conckusions Valsartan may prevent remodeling of left atrial in Af patients by reducing the level of myocardial collagen and delay the enlargement of the left atrium. Valsartan is helpful in reducing the recurrence rate of cardiocerebral events in Af patients. ......

您现在查看是摘要页,全文长 8491 字符